Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth E Sherman

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Plos One|April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trialsTara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
Archives of Virology|August 22, 2016
Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patientsMinesh Mehta, Helal F Hetta, Enass A Abdel-Hameed, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Blood|August 15, 2002
End-stage liver disease in persons with hemophilia and transfusion-associated infectionsJames J Goedert, M Elaine Eyster, Michael M Lederman, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 14, 2012
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfectionNorah A Terrault, Michelle E Roland, Thomas Schiano, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Kidney International Reports|February 14, 2022
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) TrialMeghan Elizabeth Sise, David Seth Goldberg, Douglas Earl Schaubel, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2013
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trialsJames C Sullivan, Sandra De Meyer, Doug J Bartels, et al.
Plos One|April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trialsTara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
Archives of Virology|August 22, 2016
Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patientsMinesh Mehta, Helal F Hetta, Enass A Abdel-Hameed, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2018
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 StudyJürgen K Rockstroh, Karine Lacombe, Rolando M Viani, et al.
Blood|August 15, 2002
End-stage liver disease in persons with hemophilia and transfusion-associated infectionsJames J Goedert, M Elaine Eyster, Michael M Lederman, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 14, 2012
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfectionNorah A Terrault, Michelle E Roland, Thomas Schiano, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
Kidney International Reports|February 14, 2022
One-Year Outcomes of the Multi-Center StudY to Transplant Hepatitis C-InfeCted kidneys (MYTHIC) TrialMeghan Elizabeth Sise, David Seth Goldberg, Douglas Earl Schaubel, et al.
Hepatology (Baltimore, Md.)|July 13, 2021
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE StudyMark S Sulkowski, Juhi S Moon, Kenneth E Sherman, et al.
Pageof 22